BamSEC and AlphaSense Join Forces
Learn More

Apellis Pharmaceuticals Inc.

NASDAQ: APLS    
Share price (1/8/25): $33.00    
Market cap (1/8/25): $4.105 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 155 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Financing Agreement Dated as of May 13, 2024 Among Apellis Pharmaceuticals, Inc., as Borrower, Certain Subsidiaries of Borrower, as Guarantors, Various Lenders From Time to Time Party Hereto, and Sixth Street Lending Partners, as Administrative Agent
12/34/56
EX-10.28
from 10-K 6 pages Material contract
12/34/56
EX-10
from 10-K 6 pages Apellis Pharmaceuticals, Inc. Restricted Stock Unit Award Agreement
12/34/56
EX-10.1
from 8-K 18 pages Exchange Agreement
12/34/56
EX-10.1
from 8-K 18 pages Exchange Agreement
12/34/56
EX-10.30
from 10-K 5 pages Material contract
12/34/56
EX-10.29
from 10-K 4 pages Material contract
12/34/56
EX-10.10
from 10-K 2 pages Summary of Non-Employee Director Compensation Program
12/34/56
EX-10.1
from 8-K 18 pages Exchange Agreement
12/34/56
EX-10.1
from 10-Q 27 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Amended and Restated Supply Agreement by and Between Apellis Pharmaceuticals, Inc., Together With Apellis Switzerland Gmbh and Nof Corporation
12/34/56
EX-10.26
from 10-K 35 pages Recitals Article 1 Definitions
12/34/56
EX-10.25
from 10-K 126 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Would Likely Cause Competitive Harm to the Company, if Publicly Disclosed. Double Asterisks Denote Omissions. Collaboration and License Agreement by and Among Apellis Switzerland Gmbh Apellis Pharmaceuticals, Inc. Apl Del Holdings, LLC and Swedish Orphan Biovitrum Ab (Publ) October 27, 2020
12/34/56
EX-10.17
from 10-K 10 pages Fourth Amendment to Lease
12/34/56
EX-10.1
from 8-K 18 pages Exchange Agreement
12/34/56
EX-10.2
from 10-Q 1 page Amendment No. 1 to 2017 Employee Stock Purchase Plan of Apellis Pharmaceuticals, Inc
12/34/56
EX-10.1
from 8-K 31 pages Material contract
12/34/56
EX-10.1
from 10-Q 12 pages Third Amendment to Lease
12/34/56
EX-10.1
from 8-K 12 pages Apellis Pharmaceuticals, Inc. Executive Separation Benefits and Retention Plan
12/34/56
EX-10.1
from 8-K 31 pages Material contract
12/34/56
EX-10.2
from 10-Q 5 pages Second Amendment to Lease
12/34/56